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Summary  
Various arthrit ic disorders result from a disruption of the equilibrium between the synthesis and degradation of tissue 
• matrix macromolecules. Growth factors, particularly insulin-like growth factor-I (IGF-I), are believed to play an 
important role in maintaining this equilibrium. In this study, we determined the levels of IGF-I, IGF-II, and 
• :characterized and measured the amount of IGF-binding proteins (IGFBPs) in the synovial fluid (SF) of osteoarthrit is 
(OA), rheumatoid arthrit is (RA) patients and normal individuals. Furthermore, we characterized the IGFBP found in 
these SFs. 
:Ti~e levels of IGF-I, IGF-II and IGFBP-3 were determined by specific radioimmunoassays (RIAs). IGFBP identification 
a~ffmeasurement were carried out using the Western ligand blot (WLB) technique, and characterization performed 
by  •Western immunoblot. IGFBP-3 proteolysis was analyzed by autoradiography after incubation of SF with 
Tadiolabeled IGFBP-3. 
Results showed a statistically significant increase (P < 0.001) in the IGF-I level in arthrit ic SF vs normal controls; 
~]5 + 11 ng/ml and 82 ± 11 ng/ml were recorded for RA (N= 8) and OA (N= 10), respectively, whilst normal controls 
(N = 9) were at 19 -4-_ 7 ng/ml. No difference in the level of IGF-II was recorded between the three groups tudied. Human 
SF demonstrated the presence of IGFBP-1, -2, -3 and -4, but not that of IGFBP-5 and -6. The level of IGFBP-3 tested 
either by WLB or RIA was significantly higher (P < 0.001) in RA and OA patients. Moreover, a statistical and positive 
:correlation between the levels of IGF-I and IGFBP-3 was noted. WLB analysis indicated that the amount of IGFBP-1 
diei not vary among the groups. The levels of IGFBP-2 and -4 were significantly increased (P < 0.02) solely in the RA 
SF. Further experiments demonstrated that a limited IGFBP-3 proteolysis occurred in human SF. Moreover, the ratio 
6f total IGF over total bioactive IGFBPs was lower in RA (P < 0.05), and to a lesser extent in OA than normal 
specimens. 
This study showed the presence of four IGFBPs (1 4) in human SF for which the IGFBP-2, -3 and -4 were enhanced 
in arthritic fluid. Importantly, although proteolysis occurred in the SF, an increased amount of bioactive IGFBPs were 
present in arthrit ic SF, which may affect the bioavailabil ity of IGF-I within the art icular tissues. 
Keywords: IGF~ IGFBP, Synovial fluid, Arthrit ic diseases. 
I n t roduct ion  
NORMAL ARTICULAR CARTILAGE Consists of extra-  
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ce l lu la r  mat r ix  composed of molecu les  inc lud ing  
col lagens,  proteog lycans ,  l ink prote ins  and  
hya luron ic  acid, which are synthes ized by the 
chondrocytes .  Car t i lage  in tegr i ty  is ma inta ined  by 
the s t r ic t  regu la t ion  of the ba lance  between 
degradat ion  and synthes is  of these components .  
The factors  respons ib le  for th is  t issue homeostas i s  
are, to some extent ,  the components  of the 
synov ia l  f luid (SF), as a r t i cu la r  car t i l age  is 
avascu lar .  
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Some of the common characteristics of arthritic 
cartilage matrix in the severe stage of osteoar- 
thritis (OA) and rheumatoid arthritis (RA) are a 
decreased level of macromolecules and increased 
degradative products. This is believed to be a 
result of the proteases present in the tissue, as well 
as to ambient inflammatory mediators uch as the 
cytokines [1]. While the pro-inflammatory c to- 
kines appear esponsible also for the inhibition of 
the synthesis of some of the major cartilage 
macromolecules, including the proteoglycans, 
others agents such as growth factors have been 
postulated to modulate cartilage anabolism. 
Insulin-like growth factor (IGF) appears to be a 
likely candidate involved in the repair mechanism 
[2, 3]. 
There are two forms of IGF: IGF-I and IGF-II. 
Experiments using bovine articular cartilage 
explants have shown that IGF-I is the main 
proteoglycan stimulatory factor present in fetal 
calf serum [4] and in human SF [5]. Moreover, in 
adults, IGF-I appears to be a stimulatory [2] and 
differentiating [6] factor in the biosynthesis of the 
type II collagen [7]. IGF-II appears to act rather as 
a regulating factor for glucose uptake and as a 
growth stimulator in the development s ate [8]. 
To date, the exact role of IGF-I in arthritic 
disorders remains unclear in view of recent reports 
showing that in arthritic cartilage, even in the 
presence of an increased level of IGF-I [9, 10], the 
arthritic chondrocytes are nonresponsive to IGF-I 
stimulation [11, 12]. This observation has raised 
the possibility that a class of proteins, the 
IGF-binding proteins (IGFBPs), which show a high 
affinity for IGF and act as biomodulators of the 
IGF action, may be responsible for this phenom- 
enon [11]. The human IGFBP family consists of six 
proteins, termed IGFBP-1-6. By their binding to 
IGF, these proteins may be of prime importance in 
the modulation of the IGF biological actions on 
target issues. Therefore, the possibility exists that 
an alteration in the balance between the levels of 
IGF and IGFBP in arthritic conditions may lead to 
a disturbance in the equilibrium of that biological 
system by reducing the availability of IGF-I. 
In order to learn more about this system in 
human arthritic conditions, it appears essential to 
investigate the factors involved in the modulation 
of the hormone action. Although there have been 
(conflicting) reports on the level of IGF-I in serum 
and in SF in normal and arthritic conditions 
[5, 13-15], the variations of the levels of IGF and 
IGFBP in human arthritic SF have never been 
investigated. In this study, we evaluated which of 
the elements in the IGF system in human SF, 
including IGF-I, IGF-II and their binding proteins, 
were involved in the pathophysiology of arthritis. 
Results showed that although our findings pointed 
to a higher production of IGF-I in OA and RA SF, 
the bioavailability of the latter in the pathological 
fluid appeared to be buffered by the increased 
amount of some IGFBPs. 
Mater ia ls  and methods  
HUMAN SF SELECTION 
SF were obtained from the knee joints of 10 OA 
patients (mean age: 65 + 4 years) and eight RA 
patients (mean age: 66_+ 6 years) at time of 
arthrocentesis for diagnostic or therapeutic pur- 
poses, and nine normal controls (mean age: 62 __ 7 
years). OA and RA patients were evaluated by a 
certified rheumatologist, and the diagnosis based 
on the American College of Rheumatology criteria 
[16, 17]. Normal control specimens were obtained 
at autopsy within 12 h of death from individuals 
with no history of joint disease and with 
macroscopical normal joint tissue. After being 
collected, the samples were centrifuged (1500g, 
10 min) and the supernatant frozen at -80°C until 
further used. 
OA patients were aH treated with nonsteroidal 
anti-inflammatory drugs (NSAIDs) at the time of 
arthrocentesis. The RA patients used in this study 
were considered to have an active disease [17] at 
the time that the SF was collected, and the therapy 
consisted of one or more of the basic treatments: 
NSAIDs, corticosteroids (prednisone), gold salts 
(sodium aurothiomalate) and methotrexate. No 
patient had received any other type of treatment 
(i.e., chloroquine, D-penicillamine, levamisole, etc.) 
in the preceding 6 months prior to surgery. All 
eight patients received NSAIDs; five were given 
NSAIDs only; one received steroids in combination 
with gold compounds, and two received a 
steroid-methotrexate combination therapy. 
RADIOIMMUNOASSAYS (RIA) 
IGF  measurement  
Total IGF-I or IGF-II (free and bound to IGFBP) 
was determined by RIA assays following a formic 
acid-acetone treatment, as previously described 
[10, 18, 19]. Briefly, the treatment consisted of 
acidifying SF with 8M formic acid (Fisher 
Scientific, Nepean, Ontario, Canada), containing 
0.5% Tween 20 (BioRad Laboratories Ltd, 
Mississauga, Ontario, Canada), followed by the 
addition of acetone (70% of the final volume) and 
centrifuged at 3500g for 15min at 4°C. The 
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restflting supernatant was neutralized by dilution 
iJl the t~tA buffer (see below) at 1:100 for IG F-I and 
t:200 rot IGF-II and used directly for IGF 
measu~ement~ 
I~ preliminary experiments, the efficiency of the 
treatment ( o release the IGF-IGFBP complex) was 
ev~|~ated.following the Abribat et al. method [18]. 
I~ ~ is  experiment, he human SF, untreated or 
]~c  acid:acetone-treated, were incubated 
~ '~ht  at"i:.~2°C with either [r~5I]-IG F-I (Fig. 1) or 
~]~: I I  (:~ata not illustrated) 100 000 cpm). 
~ ~his period, each sample was chromato- 
g~. a ~  on a Biogel P60 column (Pharmacia Fine 
P_ ,h~ats .  Piscataway, NJ, U.S.A.), eluted with a 
~ phosphate buffer, pH 7.4, containing 0.25% 
~ s emim albumin (BSA; Sigma Chemical 
Co ,any ,  Mississauga, Ontario, Canada) and 
1 ~  NaC1, and each fYaction subjected to a 
gat~m~ counter. As il lustrated in Fig. ], results 
Sho~ed ~hat at least 95% of the complex were 
unbound after this treatment, and the recovery of 
radio labeled IGF-I added to the SF was greater 
tha~ 95%. 
The RIAs swere performed using rhIGF-I or 
rhIGF-II (Bachem California, Torrence, CA, 
U.S.A.) radioiodinated using the chloramine 2' 
method, as previously described [20]. Rabbit 
humau IGF-I antiserum was generously provided 
hy Drs E. Underwood and J.J. Van Wyk 
(University of North Carolina, Chapel Hill, North 
Carolina, U.S.A.) through the National Hormone 
andPi tu i tary  Program of the National Institute of 
Diabetes, Digestive and Kidney Diseases. Mono- 
cional anti-human IGF-II was purchased from 
Amano International Enzyme Co. (Troy, VA, 
U.S.A.). 
The assay was conducted in a RIA buffer 
consisting of 30 mM phosphate buffer, pH 7.4, 
0:02% protamine sulfate (grade II), 10 mM EDTA, 
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Fro. 1. Biogel P60 chromatography elution profile of 
human synovial fluid (SF) non-treated (---) or formic 
acid-acetone-treated (...) incubated with [~2sI]-IGF-I. The 
solid line represents he elution profile of [~2~I]-IGF-I. 
0.02% sodium azide and 0.25% BSA (Fraction /J, 
Sigma Chemical Company). Each sample was 
incubated at 4°C for 24 h with the antibody (final 
dilution, 1:20000 for anti-IGF-I; 1:50 000 for 
anti-IGF-II), [~I]-IGF-I or ['~I]-IGF-II tracer 
(10000 cpm/ml) and the RIA buffer. After this 
period, the second antibody (IGF-I, goat anti-rabbit 
IgG; IGF-II, goat anti-mouse IgG~, Linco Research 
Inc., St. Louis, Me,  U.S.A.) was added for an 
additional 24h at 4°C. The solution was cen- 
trifuged, and the radioactivity in the pellet 
counted. Total and nonspecific binding were deter- 
mined by omitting either the IGF or the primary 
antibody, respectively. Intra- and inter-assay 
coefficients of variation for IGF-I were 4 and 13%, 
respectively, and 3 and 12%, respectively, for 
IGF-II. 
IGFBP-3  
The IGFBP-3 RIA was performed according to 
the Gargosky et al. [21] procedure with modifi- 
cations. Radioiodination of nonglycosylated 
rhIGFBP-3 (generously provided by l)r C. Maack, 
Celtrix Pharmaceuticals Inc., Santa Clara, CA, 
U.S.A.) was performed using the chloramine T 
procedure [20]. Polyclonal antiserum against the 
IGFBP-3 was produced in our lab using New 
Zealand rabbits. 
The RIA was conducted in a RIA buffer 
consisting of 30 mM phosphate butter, pH 7.4, 0.1% 
Tween, 0.1% BSA, 10 mM EDTA and 0.1% sodium 
azide. Each sample (dilution 1:100 in the RIA 
buffer) was incubated at 4°C for 24h with the 
anti-IGFBP-3 (final dilution, 1:120 000, ['2'~I-IGFBP- 
3 (10 000 cpm/ml), pig serum (5.2% v/v) and the RIA 
buffer. After this period, the second antibody (goat 
anti-rabbit IgG, Link Research In(:.) was added for 
an additional 24h at 4°C. The solution was 
centrifuged and the radioactivity in the pellet 
counted. Total and nonspecific binding were deter- 
mined as above. Intra- and inter-assay coefficients 
of variation were 4 and 11% respectively. 
WESTERN LIGAND BLOT (WLB)  
WLB analysis was performed according to 
tIossenlop et al. [22] with modifications. In brief, 
5pl of each SF sample (dilution, 1:6 in sodium 
dodecyl sulfate (SI)S) in a nonreducing buffer) was 
electrophoresed on a 12% SDS polyacrylamide gel 
[23]. Proteins were transferred to a nitrocellulose 
membrane (BioRad) at 15V overnight in a 
Transblot-Cel l  apparatus (BioRad). The mem- 
branes were washed with TBS (0.] M Tris, pH 7.4, 
0.15M NaC1, 0.05% sodium azide) containing 
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FIG. 2. Levels of (a) IGF-I (OA = P < 0.001; RA = P < 0.001) and (b) IGF-II in human synovial fluid (SF) from normal 
(N= 9), OA (N= 10, osteoarthritis) and RA (N= 8, rheumatoid arthritis) patients. P-values were determined by the 
Student-Newman-Keul's test. 
sequentially 3% Nonidet 40 for 30 rain, 1% BSA for 
2 h and 0.1% Tween 20 for 10 min. The membrane- 
immobilized proteins were incubated with [125I]- 
IGF-I (1.4×105cpm/ml) with TBS and 0.1% BSA, 
washed several times in TBS and 0.1% Tween 20, 
followed by a wash in TBS, air dried, and 
visualized by an autoradiography in the presence 
of intensifying screens overnight at -80°C. For 
quantitative analysis, bands on the nitrocellulose 
membranes corresponding to those on autoradio- 
grams were cut and the radioactivity counted in a 
gamma counter. 
WESTERN IMMUNOBLOT 
Five microliters of SF (dilution, 1:9 in SDS 
reducing buffer) was electrophoresed on a discon- 
tinuous 4-12% SDS polyacrylamide gel. Proteins 
were transferred to a nitrocellulose membrane 
(Hybond C extra, Amersham Canada Ltd., 
Oakville, Ontario, Canada) according to the 
method of Towbin et al. [24]. The efficiency of the 
transfer was controlled by the reversible Ponceau 
S staining procedure (Sigma). The membranes were 
blocked for 1 h with PBS containing 5% skim milk 
and washed twice with PBS containing 0.05% 
Tween 20 for 15 rain. Membrances were incubated 
in PBS containing 0.05% Tween 20 and 0.25% skim 
milk for 1 h with either anti-h IGFBP-1 (generously 
provided by Dr R.C. Baxter, Royal Prince Hospital, 
Camperdown, Australia), anti-h IGFBP-2, -5 (UBI, 
Lake Placid, NY, U.S.A.), anti-h IGFBP=3 (see 
IGFBP-3 RIA), or anti-h IGFBP-4 and anti-h 
IGFBP-6 (Austral Biologicals, San Ramon, CA, 
U.S.A.). These polyclonal antibodies raised in 
polyclonal rabbit were used at a dilution of 1:1000 
except for the IGFBP:4 and IGFBP-6 where 1:100 
were utilized. After an incubation period of i h, the 
membranes were washed twice and incubated at 
room temperature for 1 h with the second antibody 
(labeled horseradish peroxidase anti-rabbit IgG, 
Amersham Canada Ltd.), washed and complexed 
with a chemoluminescent reagent (ECL Kit, 
Amersham Canada Ltd.), and exposed to X-ray film. 
For each antibody, preliminary experiments were 
carried out with human recombinant IGFBP as a 
positive control. 
IGFBP IMMUNOPRECIPITATION 
Five hundred microliters of the SF (dilution 1:2 
with PBS) were incubated with protein-A agarose 
(BioRad) and nonspecific IgG (Dimension Labora- 
tories Inc., Mississauga, Ontario, Canada) for 2 h 
at 4°C. The latter was used in order to prevent 
nonspecific immunoreaction. The samples were 
centrifuged (10 000 g, 5 rain) and the supernatant 
mixed again with protein-A agarose and the  
specific antibody IGFBP (dilution 1:500 in PBS), 
and incubated at 4°C for 18 h. The immunoprecip- 
itate was collected after a centrifugation, washed 
twice in PBS/0.05% Tween 20, and the resulting 
immunoprecipitates subsequently analyzed. 
IGFBP-3 PROTEOLYSIS ANALYSIS 
Protease activity against IGFBP-3 in SF was 
tested according to the procedure of Lamson et al. 
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Fro. 3. (a) Western l igand blot (WLB) of radiolabeled IGF-I of human synovial fluid (SF) from normal  (N= 9), 
osteoarthrit ic (OA; N= 10) and rheumatoid arthrit is (RA; N=8)  patients, kDa represents the molecular  weight 
standards. (b) Quantitated analysis of WLB 30 kDa, 33 kDa, 38/42 kDa and 24 kDa bands. IGFBP-2: RA = P < 0.02; 
IGFBP-3: OA = P < 0.05, RA = P < 0.001; IGFBP-4: RA = P < 0.02. P values were determined by the Student -Keu l  test 
comparing arthrit ic specimens with normals. 
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Immunoprecipitation 
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FIG. 4. Immunoblot of human synovial fluid (SF) IGFBP from pooled normal (N), osteoarthritic (OA) and rheumatoid 
arthritis (RA) specimens. Specific antibodies against human IGFBP were as described in Materials and methods, kDa 
represents the molecular weight standards, and BP-4 the human recombinant IGFBP-4 (UBI). IGFBP-1 was 
immunoprecipitated, and IGFBP-2, -3 and -4 detected by Western immunoblott~ng. 
[25] with modifications. In brief, each sample was 
incubated with PBS containing 0.5 mM CaC12 and 
[12~I]-IGFBP-3 (2500-3000 cpm) for 4 h at 37°C. After 
this period, a nonreducing SDS-PAGE buffer was 
added and the solution electrophoresed in 12% poly- 
acrylamide gels at 60 V overnight. Gels were then 
equilibrated in a drying solution (40% methanol, 
10% acetic acid, 3% glycerol), dried under vacuum 
and visualized by autoradiography, as described 
above. The controls consisted of the [I~sI]-IGFBP-3 
with or without human full-term pregnancy serum 
(known to contain proteases degrading IGFBP-3) 
[26, 27] incubated for 4 h at 37°C. 
DATA ANALYSIS 
Values were expressed as the mean_+ SEM. 
Correlation studies were performed according 
Pearson Product Moment Correlation. Statistical 
analysis was carried out with an one-way analysis 
of variance. When differences were found, the 
Student-Newman Keul's test was used. Statistical 
differences were confirmed only when the prob- 
ability values were equal or less than 5%. 
Resu l ts  
The level of IGF-I in SF was significantly 
increased (P < 0.001), by about four times in both 
OA and RA samples when compared with normal 
individuals (Fig. 2). No difference could be seen 
between OA and RA groups. The IGF-II level in 
human SF (Fig. 2) was much higher than that 
recorded for IGF-I and, in contrast with IGF-I, no 
difference was found between the three groups 
studied. 
The WLB performed with [12~I]-IGF-I revealed 
bands at a molecular weight corresponding to the 
IGFBPs [28] (Fig. 3). In human SF, a doublet at 
42/38 kDa and bands at 33 kDa, 30 kDa and 24 kDa 
were found. Immunoblot (Fig. 4) indicated that 
they appeared to correspond to IGFBP-3 (doublet 
42/38 kDa), IGFBP-2 (33 kDa), IGFBP-1 (30 kDa) 
and IGFBP-4 (24 kDa). The IGFBP-5 and -6 could 
not be detected even after immunoprecipitation 
(not illustrated). 
Analysis of the WLB bands [Fig. 3(b)] revealed 
that IGFBP-1 was present in a similar amount in 
all three groups studied. The IGFBP-2 and 
IGFBP-4 levels were enhanced significantly 
(P < 0.02) only in the RA specimens. IGFBP-3 was 
increased significantly in both OA (P < 0.05) and 
RA (P < 0.001)specimens. Ratio of total IGF over 
total IGFBPs (WLB) revealed lower values in RA 
(0.30) (P < 0.05) and to a lesser extent in OA (0.62) 
when compared with normal specimens (0.72), 
suggesting the presence of an increased amount of 
free (unbound) IGFBPs in arthrit ic SF. 
The concentrat ion of IGFBP-3 was also deter- 
mined by RIA. Levels were 460_+ 41 ng/ml, 
909 ± 83 ng/ml and 926 -+ 86 ng/ml for normal, OA 
and RA, respectively. As with the WLB technique, 
the level of IGFBP-3 in OA and RA specimens was 
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s~¢ant~y higher (P < 0.001) than in the normal 
con~ls .  
~ :  4 il}ustrates the immunoblot of IGFBP-1, 
-~,~ ~ a~ ~4. For IGFBP-2, -3 and -4, but not for 
~ l ,  aband smaller than these characterist ics 
.~a:~ d~t~ected. These bands were at 18 kDa for 
B~2~ ~ i8 kDa along with two smaller for BP-4, 
~ ~Da for BP-3. It should be noted that 
I ~ I  eouid be detected only after being 
~op~c ip~ated  (Fig. 4). Moreover, as illus- 
~at~d i~ Fig. 4, in addition to the band 
c~te~t ic  of BP-1 (30 kDa), a large band of 
ah¢~t~ 40~5 t~13a was also present. Further  exper- 
imma~ ~evealed that the latter represents the 
b~g of protein-A agarose, which was used as a 
~ a ~  for the immunoprecipitation. 
~h~rmore ,  correlations between the IGFBP 
va~ fc0m the WLB and IGF-I revealed that the 
I~P-3  only reached statistical significance 
(r~~;46~ P< 0.02) [Fig. 5(a)]. Moreover, when 
v~,aes fl-om the IGFBP-3 RIA were correlated with 
!~F, I ,  a positive and highly significative corre- 
la~ion (r = 0.79, P < 0.001) was recorded [Fig. 5(b)]. 
L~terestingly, when values were discriminated 
between those from normal and arthrit ic speci- 
mens, and the comparison between the WLB and 
RIA profiles done, data revealed that  values of 
some of the arthr it ic specimens in the WLB fell 
into lower values [Fig. 5(a), (b)]. This indicates 
that, in these latter specimens, less IGFBP-3 may 
bind to radioactive IGF-I. This was substantiated 
by further experiments in which IGFBP-3 from 
arthrit ic SF isolated by immunoprecipitat ion, 
followed by WLB with radiolabeled IGF-I, failed to 
demonstrate the binding of the smaller fragment 
with IGF-I (data not illustrated). 
Given the suspicion that the smaller bands, as 
seen with the immunoblot (Fig. 4), were IGFBP 
degradation products, we investigated if active 
proteases were present in human SF. Experiments 
were performed in which radiolabeled rhlGFBP-3 
was incubated with normal and arthrit ic SF 
specimens, followed by electrophoresis and auto- 
radiography. As i l lustrated in Fig. 6, proteases 
capable of degrading the IGFBP-3 were present in 
the SF; the arthrit ic specimens howing a higher 
frequency of degradative products than normal 
specimens. Moreover and as i l lustrated in Fig. 6, 
SF protease(s) appeared to be less active and in 
some cases generated ifferent proteolytic prod- 
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FiG. 5. Correlation analysis of IGFBP-3 values from (a) Western ligand blot (WLB) and (b) radioimmunoassay (RIA) 
vs IGF-I (RIA) present in the human SF. Filled dots (0) represent normal specimens, filled squares ( i )  OA specimens, 
and the empty squares (D) RA specimens. For both sets, positive and statistically significant correlations were 
obtained; WLB, r=0.46, P < 0.02; RIA, r =0.79, P < 0.001. Of note is that some of the arthritic specimen values were 
at a low level when the BP-3 was analyzed by WLB as compared with the autologous RIA values. 
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125I -IGFBP-3 Normal Osteoarthritic Rheumatoid 
arthritis 
- HPS  1 2 3 1 2 3 1 2 3 kDa 
32 
~-- 27 
18 
Control Normal Osteoarthritic Rheumatoid 
arthritis 
- HPS 4 5 6 4 5 6 4 5 6 kDa 
32 
27 
18 
FIG. 6. SF proteolysis assay of radiolabeled IGFBP-3 from six normal, six osteoarthritic and six rheumatoid arthritis 
patients. The number of patients corresponds to the first six patients of Fig. 3. In this experiment, controls with (HPS) 
or without (-) human full-term pregnancy serum were used. kDa represents the molecular weight standards. 
ucts than  those found with the human ful l -term 
pregnancy  serum. 
Discuss ion  
Cart i lage destruct ion is a p rominent  feature in 
several  in f lammatory  jo int  disorders such as OA 
and RA. A l though the in i t iators  in these diseases 
may be different, the final common pathway for 
jo int  destruct ion appears  to be the same, in that  a 
d isrupt ion of the homeostas is  occurs between the 
synthesis  and the degradat ion  favor ing the 
catabol ic  process and consequent ly  the loss of 
cart i lage.  Two operat ive  mechan isms appear  to 
occur: a matr ix  degradat ion  and an inhib i t ion of 
the synthesis  of the major  macromolecules ,  
inc luding the proteoglycans.  I t  is bel ieved that  the 
impai red contro l  of proteolyt ic  enzymes (i.e., 
meta l loproteases ,  ser ine proteases)  is responsib le 
for the increased catabol ism [1], whereas  a lack of: 
anabol ic  act ion by growth factors  would be 
responsible,  at least in part,  for the decreased 
anabol ism. 
IGF- I  has been shown to regulate  the metabol i sm 
of many cells in different systems, and to be one of 
the most  impor tant  growth  factors  af fect ing the 
synthesis  of the major  molecules found in 
cart i lage.  In human SF, IGF- I  was shown to be the 
major  anabol ic  factor  in cart i lage macromolecu le  
synthesis  [5]. Therefore,  the b ioava i lab i l i ty  of this 
growth factor  is of the utmost  s igni f icance in the 
maintenance  of the cart i lage homeostasis ,  and the 
knowledge of the IGF  system compos i t ion is of 
pr ime impor tance  in human normal  and arthr i t ic  
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~ ~~ent  Study showed that although IG F-I 
i s , l~t ! ; in  an increased amount in arthritic SF, 
th~ ,~e~ of three of the IGFBPs, more 
~ ~  the IGFBP-3, may hinder the 
~ ~ ' t y  QfIGF within the articular tissues. 
~=: t i~rature ,  limited data are available 
~ ~  IO~I~ and none concerning IGF-II in 
B~: ~ study showed a significantly 
~ ~ret  ~f IGFiI in SF from patients with 
~ ~  ~ses :  This data corroborates results 
i~om~u~repor ts  in which cells from cartilage, 
~~:m~brane  or bone, generally produced a
~ ~  of this growth factor in human OA, RA 
or ~mr/1  experimental inflammatory diseases 
~ ~  ~o~Tesponding ormal cells [10, 12, 29, 30]. 
~ o r  i ~t reeent report demonstrating that 
c ~ s  ~ such as interleukin (IL)-lfl stimulate 
~ c ~ e  IGF-I production [31] may also 
~e~: I~ a~T results because a high level of this 
~ l i~z4e  was found in arthritic articular tissues 
[1,.:~i The similar levels of IGF-I observed 
b~t~en OA and RA are also consistent with those 
found by Schalkwijk et al. [5], for which no 
difference in IGF-I concentration was found 
betwsen SF from arthritic patients having inflam- 
matory effusion or not. In addition, the differences 
between the concentrations of IGF-I and IGF-II in 
norma:] SF are also in substantial agreement with 
studies on adult human serum and chondrocyte- 
cDnditior~ed medium, in which much more IGF-II 
~an IGF-I was found [33, 34]. 
Wd detected the presence of various IGFBPs in 
human SF, which correspond to BP-1, -2, -3 and -4. 
BP-3 ~n humans is usually found as a doublet of 
38/421~Da, whereas BP-4 is found as bands of 24 
and 28 kDa, representative of the nonglycosylated 
:and glycosylated forms, respectively. In our study, 
BP:3 was found as a doublet by both techniques 
used: (WLB and immunoblot) and the 24 kDa form 
for BP-4. 
In this study, SF BP-5 and -6 could not be 
deter:ted. This is intriguing because BP-5 could 
be f6und in human bone and produced by 
fibroblasts, and BP-6 by the latter cells [35-38]. It 
could be that these proteins are present but in 
too  small of an amount o be detectable with the 
technique used, including immunoprecipitation. 
Another possibility is that extensive proteolysis 
of these BP could have occurred in the SF, as 
proteases have been demonstrated to be 
produced by bone cells [39] and proteolysis 
fragments were found for three other BPs (BP-2, -3, 
,4) in this study. Proteolysis is very likely for BP-5 
as Namet al. [40] demonstrated that human cells 
such as fibroblasts produce this BP but only 
minimal intact proteins (31 kDa) were detected and 
present mostly as fragments derived from proteo- 
lysis. 
It should be noted that there was variability 
between individuals in the WLB analysis and more 
particularly, in the SF from arthrit ic patients. 
Various explanations could be brought forth 
regarding the inter-human variability, but two of 
the major possibilities may be, the status of the 
disease, as well as the medication taken by the 
patient at the time of the fluid aspiration. In this 
study, considering the paucity of the patients 
having a specific drug regimen, we did not 
correlate the results from each patient with the 
medication. However, it is well known that some 
drugs, and especially corticosteroids, have the 
ability of decreasing IGFBP levels through 
inhibition at the gene expression level [41], and 
could explain that some RA SF have less IGFBPs. 
Nevertheless, in arthritic SF, and more particu- 
larly, in those from RA patients, the WLB analysis 
showed an elevated amount of bioactive IGFBP-2, 
-3, -4 but not of IGFBP-1. The higher amount of the 
former BPs in arthritic SF may reflect the 
metabolism of the adjacent cells. Because OA and 
RA are associated with bone loss, synovitis and 
cartilage degeneration, it is possible that the high 
amount of BP results from a release due to 
disruption of the tissue matrix and/or an increased 
stimulation of the cells present in the different 
articular tissues. Because RA is a much more 
inflammatory process than OA [42], the possibility 
exists that, in RA other cells are involved or that 
the cells producing these proteins are more 
stimulated. This is very possible because in this 
disease, articular tissues synthesize more proteins 
including cytokines [1, 32]. Interestingly, some of 
them such as interleukin-lfl (IL-lfl) for chondro- 
cytes [31] and tumor necrosis factor (TNF)-~ for 
fibroblasts [43] were shown to stimulate IGFBPs. 
The significantly higher level of BP-3 in both OA 
and RA SF, as found by either WLB or RIA, was 
in accordance with a recent study showing that 
human OA chondrocytes produced more of this BP 
[11, 44]. In addition, in various cell types including 
chondrocytes, BP-3 synthesis was shown to be 
~'upregulated by IGF-I [45- 47]. This correlates with 
our finding of a significant positive correlation 
betwen BP-3 and IGF-I found by either WLB or 
RIA. Interestingly, when values were discrimi- 
nated according to their normal or pathological 
states, data from the WLB revealed that some of 
the pathological SF were at a lower level when 
compared with the autologous RIA values. It is 
possible that this resulted from the high immunore- 
activity of the 28 kDa IGFBP-3, which in turn did 
not bind radiolabeled IGF-I. This IGFBP-3 28 kDa 
272 Tavera et  a l . :  IGF and IGFBP in arthritic SF 
variant has been documented in other biological 
fluids [21]. Whether this fragment results from 
protease activity remains to be determined. 
However, various data from this study substanti- 
ated this probability: (1) the predominance of the 
28kDa IGFBP-2 fragment in arthrit ic SF, (2) 
subsequent experiments howing that this BP-3 
smaller fragment could not bind radiolabeled 
IGF-I, and (3) the frequency of proteolysis in 
arthrit ic SF was at a higher rate than in normal 
SF. SF IGFBP proteolysis is also suggested by the 
smaller fragments found in the immunoblot of both 
BP-2 and BP-4. The ability of proteases to degrade 
these BPs has been demonstrated in other cell 
systems and more part icularly for BP-4 from bone 
cells [48]. 
The presence of proteases able to degrade BP 
was originally identified in full-term pregnancy 
serum [27, 28]. Since then, other proteases were 
also found to be produced by various cells [49-51]. 
Although the physiological consequences of 
IGFBP proteolysis on IGF action is not well 
defined, in general, it appears that the enzymatic 
cleavage of BP results in an increase of IGF action 
by a reduction of the capacity of BP to inhibit IGF 
bioactivity. In many systems, these proteases 
appeared to belong to the serine protease family 
[27, 28], and one study suggests a similarity with 
plasmin [48, 51]. Another enzyme family, possibly 
related to metalloproteases, also demonstrated its 
ability to degrade the BPs [52]. In this study, wedid 
not discriminate between the enzymes possibly 
present in human SF because many were found in 
this fluid during normal and pathological con- 
ditions [53, 54]. From the proteolysis experiment, it 
appeared that less radiolabeled IGFBP-3 was 
degraded by SF rather than by full-term pregnancy 
serum, and generated different products. This 
suggests the possibility that other enzyme types 
may be present. 
Importantly, and even if proteases are present 
with a higher frequency in arthrit ic SF, our study 
showed that a higher amount of bioactive IGFBP 
is present in RA, which may lead to a shift of the 
equilibrium between IGF and BP towards the 
formation of complexes, thus possibly decreasing 
available biologically active IGF in articular 
tissues. The data from this study demonstrates an 
evident relation between SF pathological con- 
ditions and the IGF-related system. However, if 
this is the cause or the consequence of the disease 
is yet to be determined. But in light of previous 
results [11], an abundance of IGFBPs in cartilage 
may lead to a chronic resistance of the chondro- 
cytes to the stimulation by IGF-I, hindering the 
anabolism process in this tissue. 
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